Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company...
-
NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary...
-
Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting...
-
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3 ™...
-
NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary...
-
NEW HAVEN, CONN., U.S.A., April 11, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary...
-
NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
-
NEW HAVEN, Conn., Feb. 17, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
-
NEW HAVEN, Conn., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...
-
NEW HAVEN, Conn., Dec. 16, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™...